



Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507

Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com

June 8, 2023

To,
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Copy of Newspaper Publication regarding transfer of unclaimed dividend and underlying equity shares to Investor Education and Protection Fund (IEPF)

Please find enclosed a copy of the Notice published on June 8, 2023 in Business Standard and Nava Telangana pertaining to unclaimed dividend and equity shares which are liable to be transferred to the IEPF pursuant to Section 124(6) of the Companies Act, 2013 and rules thereunder.

This is for your information and records.

Thanking you.

Yours faithfully,
For Dr. Reddy's Laboratories Limited

K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR

Encl: as above

NOTICE

Notice is hereby given to the shareholders of the Company pursuant to the provisions of Section 124(6) of the Companies Act, 2013 ('the Act') and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, including any statutory modifications or amendments for the time being in force ("the Rules").

The Act and the Rules, amongst other matters, contain provisions for transfer of all shares in respect of which dividend has not been paid or claimed by the shareholders for 7 (seven) consecutive years or more to the Investor Education and Protection Fund (IEPF) Authority.

The Company has sent individual notices to the latest available addresses of the shareholders whose dividends are lying unpaid or unclaimed for the financial year 2015-16 along with subsequent 7 (seven) consecutive year's dividend, advising them to claim the dividends on or before August 30, 2023.

Further in terms of Rule 6(3) of the Rules, the statement containing the details of name, folio number/demat account number and number of shares due for transfer is made available on the Company's website: www.drreddys.com for information and necessary action by the shareholders.

Shareholders who have not claimed their dividends from the year 2015-16 can write to the Company's Registrar & Share Transfer Agent, M/s. Bigshare Services Private Limited, 306, 3rd Floor, Right Wing, Amrutha Ville, Opp: Yashoda Hospital, Rajbhavan Road, Somajiguda, Hyderabad - 500082 (India) (email: bsshyd@bigshareonline.com) or to the Company on or before August 30, 2023, for further details and for making a valid claim for the unclaimed dividends. If no valid claim has been made, such shares will be transferred to the IEPF Account.

Any person, whose shares and unpaid/unclaimed dividends have been transferred to the IEPF, may claim the shares and unpaid/unclaimed dividends from IEPF by submitting an online application in the prescribed web form IEPF-5 available on the website: <http://www.iepf.gov.in/IEPF/corporates.html> and sending a physical copy of the same to the Nodal Officer of the Company. Please note that post transfer of unpaid and unclaimed dividend amount and shares to IEPF, no claim shall lie against the Company.

This notice is also available on the Company's website: www.drreddys.com and on the website of stock exchanges www.bseindia.com and www.nseindia.com.

Place : Hyderabad
Date : June 07, 2023

For Dr. Reddy's Laboratories Ltd.
K Randhir Singh
Company Secretary

DR. REDDY'S LABORATORIES LIMITED

Regd. Office: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India
CIN: L85195TG1984PLC004507, Tel: 91 40 4900 2900, Fax: 91 40 4900 2999
email: shares@drreddys.com, website: www.drreddys.com

imited

ri (East), Mumbai - 400 093.

ate Limited Member of Multi
ID - 28710 and SEBI Registration
hip of the Exchange.

im/dispute/complaint against the
n, may lodge their claim within 60
no claim exist against the above
been waived. The complaints so
Rules and Business Rules of the

online portal of the Exchange
available at www.mcxindia.com) in
Exchange of India Ltd., Exchange
Mumbai - 400 093 or email it at

), if any, registered through this
authorized henceforth to deal in

ommodity Exchange of India Ltd.
Sd/
gnatory - Membership Department

s for the period plus tax expense plus depreciation and
ns. EBITDA provides information regarding the operational

A divided by revenue from operations and is an indicator of
t, depreciation, amortisation, and taxes.

period / year represents the profit / loss that our Company
d. It provides information regarding the profitability of the

fit for the period / year Margin is the ratio of Restated profit
y. It provides information regarding the profitability of the
he historical performance of our business.

ited profit for the period / year divided by Average Equity for
total equity at the beginning and ending of the period. RoAE
ures our Company's profitability. RoAE is indicative of the
tribution.

ed as Earnings before interest and taxes (EBIT) divided by
is an indicator of our Company's efficiency as it measures
it generation by our Company against the capital employed.

nt of leverage, calculated as a company's interest-bearing
ts EBITDA. It shows how many years it would take for a
eld constant.

cal 2022 with listed industry peers:

a business similar to that of our Company. However, there
mpetitors and are comparable to our Company. For brief
lerring Prospectus. Further there are no global listed peer
and with similar business model to that of our Company.
arison of Key Performance Indicators.

of Equity Shares or any convertible securities, whether in a
the 18 months preceding the date of the Draft Red Herring

b) There have been no secondary sales / acquisitions of Equity Shares or any convertible securities (where promoter / promoter group entities or shareholder(s) selling shares through offer for sale in IPO or shareholder(s) having the right to nominate director(s) in the Board of the Issuer Company are a party to the transaction) equivalent to or exceeding 5% of the fully diluted paid-up share capital of the Company (calculated on the date of completion of the sale), whether in a single transaction or a group of transactions during the 18 months preceding the date of the Draft Red Herring Prospectus or the Red Herring Prospectus.

c) Further we had not undertaken any primary / new issuance of Equity Shares or any convertible securities during the period of preceding 3 years from the date of the Draft Red Herring Prospectus or the Red Herring Prospectus except for issuance of equity shares on bonus issue as disclosed in the section entitled "Capital Structure" on page 73 of the Red Herring Prospectus and there have been no secondary sales / acquisitions of Equity Shares or any convertible securities (where promoter / promoter group entities or shareholder(s) selling shares through offer for sale in IPO or shareholder(s) having the right to nominate director(s) in the Board of the Issuer Company are a party to the transaction) during the period of preceding 3 years from the date of the Draft Red Herring Prospectus or the Red Herring Prospectus

Weighted average cost of acquisition ("WACA"), IPO Floor Price and Cap Price

Since there are no such transactions to report to under (a), (b) and (c) above, comparisons of Weighted Average Cost of Acquisition (WACA) with IPO Floor Price & Cap Price is not possible.

Past Transactions	WAC	IPO Floor Price - ₹55/-	IPO Cap Price - ₹85/-
WACA of Primary Issuance	Nil	NA	NA
WACA of Secondary transactions	Nil	NA	NA

9) The Offer price is [•] times of the face value of the Equity Shares.

The Offer Price of ₹ [•] has been determined by our Company and the Promoter Selling Shareholder in consultation with the Book Running Lead Manager on the basis of the assessment of market demand from investors for the Equity Shares determined through the Book Building Process and is justified based on the above qualitative and quantitative parameters. The Face Value of the Equity Shares is ₹ 10 per share and the Offer Price is [•] times of the face value. Investor should read the above mentioned information along with the section titled "Risk Factors" on page no. 25 of the Red Herring Prospectus and the financials of our Company including important profitability and return ratios, as set out in the section titled "Financial Information" on page no. 210 of the Red Herring Prospectus. The trading price of the Equity Shares could decline due to the factors mentioned in section titled "Risk Factors" on page no. 25 of the Prospectus.

